IDEAYA Biosciences, Inc. (IDYA)
IDYANASDAQ-GSBiotechnology: Pharmaceutical Preparations
$32.03
+0.7900 (+2.53%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $3.10bn
- P/E
- –
- EPS, last 4 quarters
- $-4.49
- Dividend yield
- –
- Day range
- –
- 52-week range
- $26.81 to $42.68
- Average volume
- 905.4k
- Previous close
- $31.24
Analysts
11 coveringBuy11 buy, 0 hold, 0 sell
Targets a year out average $51.27, +60.1% from here
Earnings
next estimate $-1.18Next report
Dec 2025
+8.7%
Mar 2026
-3.7%
Jun 2026
-3.4%
Sep 2026
+3.2%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $10.88m | $6.56m | $8.86m | $10.24m |
| Gross profit | $10.88m | $6.56m | $8.86m | $10.24m |
| Operating income | -$94.57m | -$108.54m | -$122.29m | -$137.63m |
| Net income | -$83.27m | -$98.54m | -$112.45m | -$125.75m |
Last four quarters: revenue $36.54m, margin -1149.6%, free cash flow -$349.80m
News
8 latest- IDEAYA Biosciences, Inc. Reports Third Quarter 2026 Financial Results and Closes Phase 3 OptimUM-010 TrialFintel · 7 days ago
- IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue EstimatesZacks · 7 days ago
- Vertex Pharmaceuticals (VRTX) Misses Q3 Earnings EstimatesZacks · Nov 2, 2026
- Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to DeclineZacks · Oct 28, 2026
- IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks · Oct 27, 2026
- IDEAYA Reports Promising IDE849 Results In Small Cell Lung Cancer RTTNews · Oct 23, 2026
- IDEAYA Reports Improvements In OS & Tumor Shrinkage For Darovasertib In Uveal Melanoma RTTNews · Oct 19, 2026
- William Blair initiates coverage of IDEAYA Biosciences with OutperformFintel · Oct 16, 2026
The company
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small-molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- ideayabio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.